Georgiou N, Gkalpinos VK, Katsakos SD, Vassiliou S, Tzakos AG, Mavromoustakos T. Rational Design and Synthesis of AT1R Antagonists.
Molecules 2021;
26:2927. [PMID:
34069122 PMCID:
PMC8156919 DOI:
10.3390/molecules26102927]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 04/18/2021] [Accepted: 05/10/2021] [Indexed: 11/16/2022] Open
Abstract
Hypertension is one of the most common diseases nowadays and is still the major cause of premature death despite of the continuous discovery of novel therapeutics. The discovery of the Renin Angiotensin System (RAS) unveiled a path to develop efficient drugs to fruitfully combat hypertension. Several compounds that prevent the Angiotensin II hormone from binding and activating the AT1R, named sartans, have been developed. Herein, we report a comprehensive review of the synthetic paths followed for the development of different sartans since the discovery of the first sartan, Losartan.
Collapse